Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hydatidiform Mole | 27 | 2024 | 255 | 6.140 |
Why?
|
Ovarian Neoplasms | 67 | 2024 | 4872 | 3.920 |
Why?
|
Uterine Neoplasms | 34 | 2024 | 1420 | 3.310 |
Why?
|
Neoplasms, Glandular and Epithelial | 15 | 2018 | 487 | 2.460 |
Why?
|
Peritoneal Neoplasms | 20 | 2024 | 710 | 2.370 |
Why?
|
Fallopian Tube Neoplasms | 19 | 2022 | 328 | 2.210 |
Why?
|
Vulvar Neoplasms | 11 | 2024 | 263 | 2.080 |
Why?
|
Hysterectomy | 13 | 2024 | 857 | 1.800 |
Why?
|
Endometrial Neoplasms | 25 | 2022 | 1366 | 1.790 |
Why?
|
Trophoblastic Tumor, Placental Site | 4 | 2024 | 20 | 1.780 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 38 | 2024 | 11733 | 1.660 |
Why?
|
Chorionic Gonadotropin | 17 | 2024 | 457 | 1.630 |
Why?
|
Genital Neoplasms, Female | 11 | 2024 | 533 | 1.480 |
Why?
|
Gynecologic Surgical Procedures | 8 | 2018 | 284 | 1.400 |
Why?
|
Carcinoma, Endometrioid | 10 | 2019 | 276 | 1.250 |
Why?
|
Pregnancy | 78 | 2024 | 29893 | 1.250 |
Why?
|
Choriocarcinoma | 5 | 2022 | 121 | 1.190 |
Why?
|
Methotrexate | 17 | 2024 | 1718 | 1.180 |
Why?
|
Neoplasm Recurrence, Local | 35 | 2023 | 9278 | 1.120 |
Why?
|
Cystadenocarcinoma, Serous | 10 | 2022 | 478 | 0.990 |
Why?
|
Dactinomycin | 12 | 2024 | 304 | 0.930 |
Why?
|
Neoplasm Staging | 53 | 2021 | 11119 | 0.890 |
Why?
|
Carcinoma, Squamous Cell | 11 | 2024 | 4021 | 0.810 |
Why?
|
Neoadjuvant Therapy | 12 | 2024 | 2827 | 0.800 |
Why?
|
Deoxycytidine | 3 | 2024 | 878 | 0.780 |
Why?
|
Adenocarcinoma, Clear Cell | 7 | 2015 | 217 | 0.770 |
Why?
|
Female | 208 | 2024 | 392544 | 0.770 |
Why?
|
CA-125 Antigen | 7 | 2017 | 281 | 0.720 |
Why?
|
Cisplatin | 5 | 2024 | 1652 | 0.680 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 6 | 2019 | 194 | 0.680 |
Why?
|
Neoplasm, Residual | 9 | 2021 | 1008 | 0.640 |
Why?
|
Disease-Free Survival | 27 | 2021 | 6819 | 0.600 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2024 | 801 | 0.600 |
Why?
|
Carcinoma in Situ | 7 | 2022 | 791 | 0.580 |
Why?
|
Granulosa Cell Tumor | 3 | 2019 | 77 | 0.570 |
Why?
|
Pregnancy Complications, Neoplastic | 3 | 2017 | 258 | 0.560 |
Why?
|
Lymph Node Excision | 5 | 2019 | 1270 | 0.540 |
Why?
|
Humans | 209 | 2024 | 761208 | 0.530 |
Why?
|
Antineoplastic Agents | 13 | 2021 | 13632 | 0.520 |
Why?
|
Quinazolines | 4 | 2022 | 1371 | 0.520 |
Why?
|
Organoplatinum Compounds | 4 | 2013 | 407 | 0.500 |
Why?
|
Remote Consultation | 1 | 2018 | 237 | 0.500 |
Why?
|
Vacuum Curettage | 3 | 2021 | 44 | 0.490 |
Why?
|
Brazil | 13 | 2023 | 1228 | 0.450 |
Why?
|
Middle Aged | 102 | 2024 | 220853 | 0.420 |
Why?
|
Uterine Cervical Neoplasms | 8 | 2021 | 2019 | 0.420 |
Why?
|
Retrospective Studies | 68 | 2024 | 80674 | 0.410 |
Why?
|
Drug Resistance, Neoplasm | 13 | 2023 | 5300 | 0.390 |
Why?
|
Chemotherapy, Adjuvant | 17 | 2024 | 3512 | 0.390 |
Why?
|
Adnexal Diseases | 2 | 2011 | 104 | 0.380 |
Why?
|
Adult | 85 | 2024 | 221119 | 0.370 |
Why?
|
Maternal Age | 4 | 2019 | 809 | 0.350 |
Why?
|
Carboplatin | 11 | 2022 | 793 | 0.340 |
Why?
|
Pelvic Neoplasms | 1 | 2011 | 247 | 0.340 |
Why?
|
Prognosis | 25 | 2024 | 29687 | 0.330 |
Why?
|
Aged | 72 | 2024 | 169288 | 0.330 |
Why?
|
Angiogenesis Inhibitors | 4 | 2013 | 2047 | 0.320 |
Why?
|
Etoposide | 6 | 2024 | 635 | 0.310 |
Why?
|
Carcinosarcoma | 3 | 2015 | 106 | 0.310 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2011 | 333 | 0.300 |
Why?
|
Topotecan | 2 | 2006 | 131 | 0.290 |
Why?
|
Obesity | 5 | 2020 | 12939 | 0.290 |
Why?
|
Disease Management | 4 | 2024 | 2507 | 0.280 |
Why?
|
Risk Factors | 26 | 2024 | 74239 | 0.260 |
Why?
|
Aged, 80 and over | 35 | 2021 | 58952 | 0.260 |
Why?
|
Treatment Outcome | 31 | 2022 | 64681 | 0.260 |
Why?
|
Needs Assessment | 1 | 2012 | 1141 | 0.250 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 697 | 0.250 |
Why?
|
Bile Acids and Salts | 1 | 2007 | 394 | 0.240 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2020 | 646 | 0.240 |
Why?
|
Genes, BRCA1 | 4 | 2021 | 754 | 0.240 |
Why?
|
Feasibility Studies | 6 | 2024 | 5250 | 0.240 |
Why?
|
Leucovorin | 5 | 2021 | 643 | 0.230 |
Why?
|
Venous Thromboembolism | 3 | 2019 | 1869 | 0.230 |
Why?
|
Telemedicine | 5 | 2024 | 3051 | 0.230 |
Why?
|
Radiotherapy, Adjuvant | 8 | 2019 | 1784 | 0.230 |
Why?
|
Protein Kinase Inhibitors | 3 | 2012 | 5662 | 0.230 |
Why?
|
Cohort Studies | 22 | 2023 | 41496 | 0.230 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2019 | 899 | 0.220 |
Why?
|
Patient Readmission | 3 | 2020 | 3265 | 0.220 |
Why?
|
Drug Administration Schedule | 10 | 2021 | 4851 | 0.220 |
Why?
|
Suction | 2 | 2020 | 266 | 0.220 |
Why?
|
Risk | 7 | 2022 | 9616 | 0.210 |
Why?
|
Models, Statistical | 1 | 2017 | 5081 | 0.210 |
Why?
|
Carcinoma | 3 | 2022 | 2330 | 0.210 |
Why?
|
Carcinoma, Papillary | 3 | 2014 | 785 | 0.210 |
Why?
|
Pneumatosis Cystoides Intestinalis | 1 | 2002 | 31 | 0.200 |
Why?
|
Myometrium | 2 | 2014 | 174 | 0.200 |
Why?
|
Hyperthyroidism | 2 | 2022 | 294 | 0.200 |
Why?
|
Sexual Behavior | 1 | 2012 | 2189 | 0.190 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2002 | 65 | 0.190 |
Why?
|
Blood Transfusion, Autologous | 1 | 2002 | 130 | 0.190 |
Why?
|
Paclitaxel | 10 | 2022 | 1730 | 0.190 |
Why?
|
Laparoscopy | 4 | 2024 | 2035 | 0.190 |
Why?
|
Endometrial Hyperplasia | 1 | 2002 | 97 | 0.190 |
Why?
|
Young Adult | 25 | 2024 | 59221 | 0.190 |
Why?
|
Genes, BRCA2 | 2 | 2015 | 591 | 0.190 |
Why?
|
Lymph Nodes | 4 | 2016 | 3461 | 0.190 |
Why?
|
Enzyme Inhibitors | 1 | 2012 | 3702 | 0.190 |
Why?
|
Cyclodextrins | 1 | 2021 | 66 | 0.190 |
Why?
|
DNA Repair | 2 | 2018 | 2041 | 0.190 |
Why?
|
Survivors | 1 | 2012 | 2369 | 0.180 |
Why?
|
Brachytherapy | 2 | 2014 | 1223 | 0.180 |
Why?
|
Gravidity | 2 | 2021 | 50 | 0.180 |
Why?
|
Genital Diseases, Female | 1 | 2002 | 192 | 0.180 |
Why?
|
Doxorubicin | 3 | 2020 | 2224 | 0.180 |
Why?
|
Uterine Artery | 1 | 2020 | 30 | 0.180 |
Why?
|
Growth Differentiation Factor 2 | 1 | 2020 | 27 | 0.180 |
Why?
|
Kaplan-Meier Estimate | 9 | 2019 | 6486 | 0.180 |
Why?
|
Survival Rate | 12 | 2020 | 12728 | 0.180 |
Why?
|
Intestinal Perforation | 1 | 2002 | 249 | 0.180 |
Why?
|
Microsatellite Repeats | 1 | 2002 | 782 | 0.170 |
Why?
|
Blood Donors | 1 | 2002 | 345 | 0.170 |
Why?
|
Ultrasonic Therapy | 1 | 2001 | 215 | 0.170 |
Why?
|
Parity | 2 | 2016 | 929 | 0.170 |
Why?
|
Iodide Peroxidase | 1 | 2021 | 294 | 0.170 |
Why?
|
Fallopian Tubes | 2 | 2018 | 178 | 0.160 |
Why?
|
Ostomy | 1 | 2019 | 33 | 0.160 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2022 | 348 | 0.160 |
Why?
|
Uterine Hemorrhage | 3 | 2017 | 240 | 0.160 |
Why?
|
New England | 6 | 2017 | 1052 | 0.160 |
Why?
|
DNA Polymerase II | 1 | 2019 | 104 | 0.150 |
Why?
|
Pyrimidinones | 1 | 2021 | 385 | 0.150 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 218 | 0.150 |
Why?
|
Precancerous Conditions | 3 | 2018 | 982 | 0.150 |
Why?
|
Paget Disease, Extramammary | 1 | 2018 | 51 | 0.150 |
Why?
|
Camptothecin | 1 | 2021 | 591 | 0.150 |
Why?
|
Mixed Tumor, Mullerian | 2 | 2008 | 55 | 0.140 |
Why?
|
Cervix Uteri | 1 | 2021 | 570 | 0.140 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2008 | 2024 | 0.140 |
Why?
|
Nomograms | 1 | 2019 | 230 | 0.140 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2019 | 287 | 0.140 |
Why?
|
Hypothyroidism | 1 | 2022 | 668 | 0.140 |
Why?
|
Cyclophosphamide | 3 | 2023 | 2219 | 0.140 |
Why?
|
Disease Progression | 4 | 2021 | 13511 | 0.140 |
Why?
|
Cysts | 1 | 2022 | 680 | 0.140 |
Why?
|
Demography | 2 | 2020 | 1641 | 0.130 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2021 | 1168 | 0.130 |
Why?
|
Insurance Coverage | 2 | 2018 | 1935 | 0.130 |
Why?
|
Adenocarcinoma | 4 | 2019 | 6341 | 0.130 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2017 | 592 | 0.130 |
Why?
|
Drug Substitution | 1 | 2019 | 291 | 0.130 |
Why?
|
Endometrium | 1 | 2019 | 403 | 0.130 |
Why?
|
Adenocarcinoma, Mucinous | 3 | 2014 | 517 | 0.130 |
Why?
|
Evidence-Based Medicine | 2 | 2021 | 3691 | 0.130 |
Why?
|
Pilot Projects | 6 | 2024 | 8642 | 0.130 |
Why?
|
Cross-Sectional Studies | 7 | 2023 | 26071 | 0.130 |
Why?
|
Early Detection of Cancer | 3 | 2021 | 3198 | 0.130 |
Why?
|
Bismuth | 1 | 1995 | 29 | 0.130 |
Why?
|
Radiopharmaceuticals | 2 | 2008 | 2683 | 0.130 |
Why?
|
Pelvis | 2 | 2014 | 735 | 0.130 |
Why?
|
Antitoxins | 1 | 1995 | 77 | 0.120 |
Why?
|
Omentum | 3 | 2019 | 167 | 0.120 |
Why?
|
Immunohistochemistry | 7 | 2019 | 11067 | 0.120 |
Why?
|
Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
Regression Analysis | 2 | 2017 | 6345 | 0.120 |
Why?
|
Caregivers | 2 | 2024 | 2244 | 0.120 |
Why?
|
Trophoblastic Neoplasms | 1 | 2015 | 88 | 0.120 |
Why?
|
Length of Stay | 3 | 2020 | 6417 | 0.120 |
Why?
|
Multivariate Analysis | 5 | 2020 | 12052 | 0.120 |
Why?
|
Maximum Tolerated Dose | 2 | 2015 | 883 | 0.120 |
Why?
|
Colposcopy | 3 | 2021 | 149 | 0.120 |
Why?
|
Lymphatic Metastasis | 7 | 2014 | 2913 | 0.120 |
Why?
|
Receptors, Estrogen | 2 | 2022 | 2208 | 0.120 |
Why?
|
Cystadenocarcinoma, Papillary | 2 | 2006 | 56 | 0.120 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2017 | 246 | 0.120 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2020 | 1241 | 0.110 |
Why?
|
Receptors, Progesterone | 1 | 2019 | 1129 | 0.110 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2014 | 155 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 1404 | 0.110 |
Why?
|
Erythrocyte Transfusion | 1 | 2019 | 569 | 0.110 |
Why?
|
Diagnosis, Differential | 7 | 2019 | 12976 | 0.110 |
Why?
|
Colectomy | 1 | 2019 | 686 | 0.110 |
Why?
|
Sarcoma, Endometrial Stromal | 1 | 2014 | 93 | 0.110 |
Why?
|
Radiation Injuries | 2 | 2014 | 1191 | 0.110 |
Why?
|
Watchful Waiting | 1 | 2017 | 489 | 0.110 |
Why?
|
Apoptosis | 2 | 2020 | 9477 | 0.110 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2020 | 677 | 0.110 |
Why?
|
BRCA1 Protein | 2 | 2022 | 1149 | 0.110 |
Why?
|
Pregnancy Outcome | 2 | 2021 | 2923 | 0.110 |
Why?
|
Pyrazoles | 2 | 2021 | 2010 | 0.110 |
Why?
|
Cholera Toxin | 1 | 1995 | 559 | 0.110 |
Why?
|
Vincristine | 3 | 2023 | 1036 | 0.110 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2017 | 380 | 0.100 |
Why?
|
Registries | 4 | 2024 | 8247 | 0.100 |
Why?
|
Diagnostic Imaging | 3 | 2013 | 3534 | 0.100 |
Why?
|
Papillomavirus Infections | 3 | 2021 | 1616 | 0.100 |
Why?
|
Case-Control Studies | 10 | 2014 | 22174 | 0.100 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 479 | 0.100 |
Why?
|
Folate Receptors, GPI-Anchored | 1 | 2012 | 23 | 0.100 |
Why?
|
Survival Analysis | 7 | 2020 | 10088 | 0.100 |
Why?
|
Organoids | 1 | 2018 | 744 | 0.100 |
Why?
|
Immunity, Mucosal | 1 | 1995 | 485 | 0.100 |
Why?
|
Papillomaviridae | 2 | 2016 | 1120 | 0.100 |
Why?
|
Quality of Life | 4 | 2024 | 13367 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 2426 | 0.100 |
Why?
|
Body Mass Index | 3 | 2016 | 12952 | 0.100 |
Why?
|
Taxoids | 2 | 2012 | 668 | 0.100 |
Why?
|
Infusions, Parenteral | 3 | 2021 | 398 | 0.090 |
Why?
|
Adolescent | 17 | 2021 | 88298 | 0.090 |
Why?
|
Prenatal Diagnosis | 1 | 2018 | 1267 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2020 | 8530 | 0.090 |
Why?
|
Abortion, Induced | 1 | 2017 | 462 | 0.090 |
Why?
|
Cell Proliferation | 3 | 2020 | 10422 | 0.090 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 7400 | 0.090 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 3803 | 0.090 |
Why?
|
Follow-Up Studies | 8 | 2020 | 39126 | 0.090 |
Why?
|
Mutation | 7 | 2022 | 30002 | 0.090 |
Why?
|
Decision Making | 1 | 2024 | 3931 | 0.090 |
Why?
|
DNA Methylation | 2 | 2017 | 4384 | 0.090 |
Why?
|
Neoplasm Invasiveness | 6 | 2018 | 3590 | 0.090 |
Why?
|
Neoplasm Proteins | 1 | 2002 | 3594 | 0.090 |
Why?
|
BRCA2 Protein | 1 | 2015 | 797 | 0.090 |
Why?
|
Pre-Eclampsia | 2 | 2017 | 1233 | 0.090 |
Why?
|
Neutrophils | 1 | 2022 | 3763 | 0.090 |
Why?
|
Brain Neoplasms | 2 | 2024 | 9025 | 0.080 |
Why?
|
Age Factors | 4 | 2019 | 18384 | 0.080 |
Why?
|
Referral and Consultation | 3 | 2021 | 3608 | 0.080 |
Why?
|
Gravitation | 1 | 2009 | 82 | 0.080 |
Why?
|
Cell Death | 1 | 2015 | 1676 | 0.080 |
Why?
|
Cell Lineage | 1 | 2018 | 2548 | 0.080 |
Why?
|
Cell Cycle Proteins | 1 | 2021 | 3446 | 0.080 |
Why?
|
Phthalazines | 2 | 2022 | 383 | 0.080 |
Why?
|
Surgical Wound Infection | 1 | 2019 | 1530 | 0.080 |
Why?
|
Palliative Care | 1 | 2024 | 3599 | 0.080 |
Why?
|
Patient Acceptance of Health Care | 2 | 2024 | 3200 | 0.080 |
Why?
|
Anesthetics | 1 | 2014 | 523 | 0.080 |
Why?
|
Insurance, Health | 2 | 2018 | 2493 | 0.080 |
Why?
|
Infusions, Intravenous | 4 | 2020 | 2217 | 0.080 |
Why?
|
Germ-Line Mutation | 2 | 2015 | 1852 | 0.080 |
Why?
|
Nursing Homes | 1 | 2016 | 1083 | 0.080 |
Why?
|
Stomach Neoplasms | 1 | 2019 | 1457 | 0.080 |
Why?
|
Radiology | 2 | 2013 | 2112 | 0.080 |
Why?
|
South America | 2 | 2020 | 180 | 0.080 |
Why?
|
Time Factors | 8 | 2020 | 39957 | 0.080 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2018 | 2820 | 0.080 |
Why?
|
Folic Acid | 1 | 2015 | 1323 | 0.080 |
Why?
|
Remission Induction | 3 | 2020 | 2392 | 0.070 |
Why?
|
Cholic Acid | 1 | 2007 | 31 | 0.070 |
Why?
|
Tetrazolium Salts | 1 | 2007 | 92 | 0.070 |
Why?
|
Genes, erbB-1 | 1 | 2008 | 162 | 0.070 |
Why?
|
Polyethylene Glycols | 2 | 2020 | 1187 | 0.070 |
Why?
|
Chenodeoxycholic Acid | 1 | 2007 | 34 | 0.070 |
Why?
|
Deoxycholic Acid | 1 | 2007 | 53 | 0.070 |
Why?
|
Membrane Proteins | 2 | 2017 | 7851 | 0.070 |
Why?
|
Ursodeoxycholic Acid | 1 | 2007 | 81 | 0.070 |
Why?
|
Hedgehog Proteins | 1 | 2012 | 769 | 0.070 |
Why?
|
Abdomen | 1 | 2013 | 1128 | 0.070 |
Why?
|
Vulva | 1 | 2007 | 84 | 0.070 |
Why?
|
Intensive Care Units | 2 | 2017 | 3744 | 0.070 |
Why?
|
Contraceptives, Oral | 1 | 2009 | 554 | 0.070 |
Why?
|
Exercise | 2 | 2021 | 5874 | 0.070 |
Why?
|
Ovariectomy | 2 | 2022 | 614 | 0.070 |
Why?
|
Epithelial Cells | 1 | 2018 | 3671 | 0.070 |
Why?
|
Breast Neoplasms | 4 | 2022 | 20982 | 0.070 |
Why?
|
Costs and Cost Analysis | 1 | 2012 | 1664 | 0.070 |
Why?
|
United States | 11 | 2021 | 72339 | 0.070 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2014 | 1520 | 0.070 |
Why?
|
Tomography, Spiral Computed | 1 | 2008 | 273 | 0.070 |
Why?
|
Postoperative Complications | 5 | 2020 | 15637 | 0.070 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 664 | 0.070 |
Why?
|
Weight Loss | 1 | 2017 | 2680 | 0.070 |
Why?
|
Pyrroles | 1 | 2012 | 1124 | 0.070 |
Why?
|
Intestinal Obstruction | 1 | 2010 | 432 | 0.060 |
Why?
|
Research Design | 1 | 2022 | 6180 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2023 | 5425 | 0.060 |
Why?
|
Endometriosis | 1 | 2014 | 870 | 0.060 |
Why?
|
Ligands | 2 | 2022 | 3264 | 0.060 |
Why?
|
Patient Discharge | 2 | 2016 | 3441 | 0.060 |
Why?
|
Predictive Value of Tests | 3 | 2017 | 15308 | 0.060 |
Why?
|
Pulmonary Embolism | 1 | 2019 | 2571 | 0.060 |
Why?
|
Coloring Agents | 1 | 2007 | 561 | 0.060 |
Why?
|
Genes, MDR | 1 | 2004 | 36 | 0.060 |
Why?
|
Combined Modality Therapy | 5 | 2012 | 8519 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10218 | 0.060 |
Why?
|
MicroRNAs | 1 | 2020 | 3758 | 0.060 |
Why?
|
Family Health | 1 | 2009 | 1254 | 0.060 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2013 | 782 | 0.060 |
Why?
|
Abortion, Spontaneous | 2 | 2021 | 533 | 0.060 |
Why?
|
Indoles | 1 | 2012 | 1830 | 0.060 |
Why?
|
Microvessels | 1 | 2008 | 580 | 0.060 |
Why?
|
Drug Costs | 1 | 2012 | 1183 | 0.060 |
Why?
|
Overweight | 1 | 2015 | 2418 | 0.060 |
Why?
|
Nucleosomes | 1 | 2007 | 486 | 0.060 |
Why?
|
Platinum Compounds | 2 | 2014 | 95 | 0.060 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2007 | 384 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2018 | 2915 | 0.050 |
Why?
|
Cellular Structures | 1 | 2022 | 9 | 0.050 |
Why?
|
Preoperative Care | 1 | 2012 | 2241 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2012 | 2455 | 0.050 |
Why?
|
Protein Kinase C | 1 | 2007 | 1202 | 0.050 |
Why?
|
Ribose | 1 | 2022 | 63 | 0.050 |
Why?
|
Base Pair Mismatch | 1 | 2002 | 92 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3093 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 89 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3215 | 0.050 |
Why?
|
Laparotomy | 1 | 2024 | 456 | 0.050 |
Why?
|
Sperm Injections, Intracytoplasmic | 1 | 2023 | 156 | 0.050 |
Why?
|
Peritoneal Cavity | 1 | 2022 | 135 | 0.050 |
Why?
|
Proportional Hazards Models | 5 | 2018 | 12474 | 0.050 |
Why?
|
Fertilization | 1 | 2023 | 198 | 0.050 |
Why?
|
Administration, Intravaginal | 1 | 2002 | 149 | 0.050 |
Why?
|
Blood Cell Count | 1 | 2022 | 396 | 0.050 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2004 | 714 | 0.050 |
Why?
|
Medical Oncology | 1 | 2013 | 2320 | 0.050 |
Why?
|
Lutein | 1 | 2022 | 123 | 0.050 |
Why?
|
Vagina | 1 | 2007 | 841 | 0.050 |
Why?
|
Antibodies, Monoclonal | 4 | 2022 | 9187 | 0.050 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2020 | 3634 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 5366 | 0.050 |
Why?
|
Lymphatic System | 1 | 2002 | 253 | 0.050 |
Why?
|
SEER Program | 2 | 2018 | 1453 | 0.050 |
Why?
|
Hysteroscopy | 1 | 2021 | 62 | 0.040 |
Why?
|
Biopsy | 2 | 2004 | 6781 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2012 | 2813 | 0.040 |
Why?
|
Signal Transduction | 2 | 2015 | 23416 | 0.040 |
Why?
|
Neoplasms | 2 | 2022 | 22140 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2020 | 148 | 0.040 |
Why?
|
Prospective Studies | 6 | 2022 | 54435 | 0.040 |
Why?
|
Ascites | 2 | 2017 | 338 | 0.040 |
Why?
|
Semen | 1 | 2023 | 347 | 0.040 |
Why?
|
Self Efficacy | 1 | 2024 | 636 | 0.040 |
Why?
|
Thiazoles | 1 | 2007 | 1517 | 0.040 |
Why?
|
Radiation Dosage | 2 | 2014 | 1962 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2021 | 14675 | 0.040 |
Why?
|
X-Rays | 1 | 2021 | 307 | 0.040 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13385 | 0.040 |
Why?
|
Positron-Emission Tomography | 2 | 2008 | 6585 | 0.040 |
Why?
|
Community Health Centers | 1 | 2023 | 461 | 0.040 |
Why?
|
Electrocoagulation | 1 | 2020 | 151 | 0.040 |
Why?
|
Drug Interactions | 1 | 2004 | 1417 | 0.040 |
Why?
|
Guideline Adherence | 1 | 2010 | 2220 | 0.040 |
Why?
|
Selenoproteins | 1 | 2021 | 215 | 0.040 |
Why?
|
Adnexa Uteri | 1 | 2019 | 40 | 0.040 |
Why?
|
Abortion, Habitual | 1 | 2019 | 61 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2022 | 428 | 0.040 |
Why?
|
Cell Line, Tumor | 2 | 2007 | 16952 | 0.040 |
Why?
|
Fibrinolytic Agents | 1 | 2009 | 2075 | 0.040 |
Why?
|
Neoplasm Metastasis | 3 | 2016 | 4909 | 0.040 |
Why?
|
Pneumothorax | 1 | 2002 | 386 | 0.040 |
Why?
|
Societies, Medical | 1 | 2011 | 3923 | 0.040 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2021 | 422 | 0.040 |
Why?
|
Sweden | 1 | 2002 | 1379 | 0.040 |
Why?
|
Models, Biological | 1 | 2015 | 9457 | 0.040 |
Why?
|
Stillbirth | 1 | 2021 | 369 | 0.040 |
Why?
|
Online Systems | 1 | 2019 | 182 | 0.040 |
Why?
|
Thyrotropin | 1 | 2022 | 833 | 0.040 |
Why?
|
Reoperation | 2 | 2020 | 4303 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2022 | 559 | 0.040 |
Why?
|
Immunotherapy | 2 | 2024 | 4642 | 0.040 |
Why?
|
Cytarabine | 1 | 2020 | 697 | 0.040 |
Why?
|
Neovascularization, Pathologic | 1 | 2008 | 2636 | 0.040 |
Why?
|
Placenta | 2 | 2022 | 1711 | 0.040 |
Why?
|
Pandemics | 3 | 2022 | 8663 | 0.040 |
Why?
|
Ultrasonography | 1 | 2010 | 5969 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2008 | 3493 | 0.040 |
Why?
|
Mass Screening | 2 | 2010 | 5426 | 0.040 |
Why?
|
Vitamin A | 1 | 2020 | 612 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6919 | 0.030 |
Why?
|
Boston | 3 | 2017 | 9327 | 0.030 |
Why?
|
Aorta | 1 | 2004 | 2040 | 0.030 |
Why?
|
Advance Care Planning | 1 | 2024 | 697 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2016 | 2509 | 0.030 |
Why?
|
Fat Necrosis | 1 | 1996 | 60 | 0.030 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2024 | 955 | 0.030 |
Why?
|
Genes, p53 | 1 | 2018 | 713 | 0.030 |
Why?
|
Medical Records | 1 | 2002 | 1409 | 0.030 |
Why?
|
Organ Culture Techniques | 1 | 2018 | 793 | 0.030 |
Why?
|
Retroperitoneal Space | 1 | 2016 | 170 | 0.030 |
Why?
|
Sodium Salicylate | 1 | 1995 | 18 | 0.030 |
Why?
|
Gastrointestinal Agents | 1 | 2001 | 509 | 0.030 |
Why?
|
Ovary | 1 | 2020 | 957 | 0.030 |
Why?
|
Pregnancy, Multiple | 1 | 2017 | 215 | 0.030 |
Why?
|
ROC Curve | 2 | 2017 | 3584 | 0.030 |
Why?
|
Drug Synergism | 1 | 2019 | 1756 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2002 | 1723 | 0.030 |
Why?
|
Salicylates | 1 | 1995 | 127 | 0.030 |
Why?
|
Chorionic Gonadotropin, beta Subunit, Human | 1 | 2015 | 82 | 0.030 |
Why?
|
Fetal Death | 1 | 2017 | 435 | 0.030 |
Why?
|
Neck | 1 | 1999 | 734 | 0.030 |
Why?
|
Administration, Oral | 2 | 2009 | 4015 | 0.030 |
Why?
|
Lymphocytes | 1 | 2022 | 2603 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1089 | 0.030 |
Why?
|
HeLa Cells | 1 | 2021 | 3073 | 0.030 |
Why?
|
Sirolimus | 1 | 2022 | 1540 | 0.030 |
Why?
|
Genetic Markers | 1 | 2020 | 2599 | 0.030 |
Why?
|
Triage | 1 | 2021 | 985 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10756 | 0.030 |
Why?
|
Equipment Design | 1 | 2001 | 3510 | 0.030 |
Why?
|
DNA Mutational Analysis | 2 | 2015 | 4107 | 0.030 |
Why?
|
Qualitative Research | 1 | 2024 | 3024 | 0.030 |
Why?
|
Live Birth | 1 | 2017 | 511 | 0.030 |
Why?
|
North America | 1 | 2017 | 1284 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2864 | 0.030 |
Why?
|
Immunoglobulin A | 2 | 1995 | 979 | 0.030 |
Why?
|
Massachusetts | 2 | 2018 | 8837 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6124 | 0.030 |
Why?
|
Observer Variation | 1 | 2019 | 2610 | 0.030 |
Why?
|
North Carolina | 1 | 2013 | 324 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2022 | 2058 | 0.030 |
Why?
|
Pyrazines | 1 | 2018 | 1202 | 0.030 |
Why?
|
Incidence | 3 | 2016 | 21365 | 0.030 |
Why?
|
Antioxidants | 1 | 2020 | 1667 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3592 | 0.020 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2016 | 732 | 0.020 |
Why?
|
Organometallic Compounds | 1 | 1995 | 647 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2022 | 2553 | 0.020 |
Why?
|
Gestational Age | 1 | 2021 | 3580 | 0.020 |
Why?
|
Vitamins | 1 | 2020 | 1634 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 4 | 2021 | 20588 | 0.020 |
Why?
|
Injections, Intraperitoneal | 1 | 2012 | 413 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2002 | 2897 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2006 | 4014 | 0.020 |
Why?
|
Splenectomy | 1 | 2013 | 391 | 0.020 |
Why?
|
Gene Dosage | 1 | 2016 | 1217 | 0.020 |
Why?
|
Diaphragm | 1 | 2013 | 351 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2021 | 3770 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2194 | 0.020 |
Why?
|
DNA Replication | 1 | 2018 | 1415 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2007 | 9416 | 0.020 |
Why?
|
Immunization | 1 | 1995 | 1218 | 0.020 |
Why?
|
Histocytochemistry | 1 | 2012 | 697 | 0.020 |
Why?
|
Radiography | 1 | 2002 | 6974 | 0.020 |
Why?
|
Motivation | 1 | 2021 | 2002 | 0.020 |
Why?
|
Perioperative Care | 1 | 2019 | 1037 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2002 | 5773 | 0.020 |
Why?
|
Intestine, Large | 1 | 2010 | 69 | 0.020 |
Why?
|
Postoperative Period | 1 | 2015 | 1818 | 0.020 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 686 | 0.020 |
Why?
|
World Health Organization | 1 | 2016 | 1321 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 3 | 2018 | 17897 | 0.020 |
Why?
|
Intestines | 1 | 2019 | 1908 | 0.020 |
Why?
|
Hepatectomy | 1 | 2013 | 557 | 0.020 |
Why?
|
Risk Assessment | 2 | 2009 | 24021 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2001 | 4340 | 0.020 |
Why?
|
Clinical Competence | 1 | 2005 | 4788 | 0.020 |
Why?
|
Blood Transfusion | 1 | 2016 | 1303 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2004 | 12747 | 0.020 |
Why?
|
DNA, Viral | 1 | 2016 | 2195 | 0.020 |
Why?
|
Immunoglobulin E | 1 | 1995 | 1505 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2020 | 3114 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2002 | 5493 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2002 | 4935 | 0.020 |
Why?
|
Feces | 1 | 1995 | 1490 | 0.020 |
Why?
|
Phenotype | 2 | 2018 | 16575 | 0.020 |
Why?
|
Pregnancy Complications | 1 | 2002 | 2949 | 0.020 |
Why?
|
Pancreatectomy | 1 | 2013 | 811 | 0.020 |
Why?
|
Mice | 3 | 2022 | 81326 | 0.020 |
Why?
|
Crohn Disease | 1 | 2001 | 2278 | 0.020 |
Why?
|
Proteomics | 1 | 2022 | 3840 | 0.020 |
Why?
|
Robotics | 1 | 2015 | 817 | 0.020 |
Why?
|
Tumor Burden | 1 | 2014 | 1892 | 0.020 |
Why?
|
Child | 4 | 2019 | 80152 | 0.020 |
Why?
|
Calcinosis | 1 | 1996 | 1477 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2002 | 5782 | 0.020 |
Why?
|
Guanine | 1 | 2008 | 278 | 0.020 |
Why?
|
Angiopoietin-2 | 1 | 2008 | 173 | 0.020 |
Why?
|
Iopamidol | 1 | 2008 | 186 | 0.020 |
Why?
|
Glutamates | 1 | 2008 | 385 | 0.020 |
Why?
|
Microdissection | 1 | 2007 | 151 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4574 | 0.020 |
Why?
|
Vaginal Neoplasms | 1 | 2007 | 104 | 0.020 |
Why?
|
Genomics | 1 | 2022 | 5828 | 0.020 |
Why?
|
Life Style | 1 | 2017 | 3907 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2014 | 1201 | 0.020 |
Why?
|
Genotype | 1 | 2019 | 12985 | 0.020 |
Why?
|
Critical Care | 1 | 2017 | 2696 | 0.010 |
Why?
|
Premature Birth | 1 | 2017 | 1784 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2007 | 748 | 0.010 |
Why?
|
Immunoglobulin G | 2 | 1995 | 4537 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9652 | 0.010 |
Why?
|
Gene Amplification | 1 | 2008 | 1084 | 0.010 |
Why?
|
Intestine, Small | 1 | 2010 | 1207 | 0.010 |
Why?
|
Animals | 3 | 2022 | 168079 | 0.010 |
Why?
|
Logistic Models | 1 | 2018 | 13249 | 0.010 |
Why?
|
Lasers | 1 | 2007 | 952 | 0.010 |
Why?
|
Necrosis | 1 | 2007 | 1610 | 0.010 |
Why?
|
Epithelium | 1 | 2007 | 1603 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26199 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3354 | 0.010 |
Why?
|
Genetic Testing | 1 | 2015 | 3537 | 0.010 |
Why?
|
Stromal Cells | 1 | 2007 | 1329 | 0.010 |
Why?
|
Mitochondria | 1 | 2015 | 3620 | 0.010 |
Why?
|
Primary Prevention | 1 | 2009 | 1185 | 0.010 |
Why?
|
Transcriptional Activation | 1 | 2007 | 1749 | 0.010 |
Why?
|
Cell Line | 1 | 2015 | 15545 | 0.010 |
Why?
|
Infant | 1 | 2023 | 36169 | 0.010 |
Why?
|
Radiotherapy | 1 | 2007 | 1499 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4567 | 0.010 |
Why?
|
Pregnancy Trimester, Third | 1 | 2002 | 583 | 0.010 |
Why?
|
Prevalence | 1 | 2017 | 15721 | 0.010 |
Why?
|
Vaginal Smears | 1 | 2002 | 499 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2007 | 3777 | 0.010 |
Why?
|
Vascular Surgical Procedures | 1 | 2007 | 1489 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2013 | 4309 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 1995 | 22127 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2014 | 11509 | 0.010 |
Why?
|
Safety | 1 | 2001 | 1151 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5321 | 0.010 |
Why?
|
Smoking | 2 | 2007 | 9055 | 0.010 |
Why?
|
Pneumonectomy | 1 | 2002 | 1118 | 0.010 |
Why?
|
Contrast Media | 1 | 2008 | 5311 | 0.010 |
Why?
|
Comorbidity | 1 | 2009 | 10516 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 36415 | 0.010 |
Why?
|
Axilla | 1 | 1996 | 624 | 0.010 |
Why?
|
Postmenopause | 1 | 2002 | 2514 | 0.010 |
Why?
|
Simplexvirus | 1 | 1976 | 801 | 0.010 |
Why?
|
Immunity | 1 | 1976 | 996 | 0.010 |
Why?
|
Male | 3 | 2023 | 360693 | 0.000 |
Why?
|
Mammography | 1 | 1996 | 2430 | 0.000 |
Why?
|
Antibodies, Viral | 1 | 1976 | 3149 | 0.000 |
Why?
|
Antibody Formation | 1 | 1976 | 1391 | 0.000 |
Why?
|
Immunoglobulin M | 1 | 1976 | 1527 | 0.000 |
Why?
|
Alcohol Drinking | 1 | 1976 | 4027 | 0.000 |
Why?
|